mirvetuximab

Key facts

Mechanism of action

Folate receptor alpha binding agent

Primary target: Folate receptor alpha

Approval history

1. D8991C00001 Phase 3 · AstraZeneca · Advanced Platinum-resistant Epithelial Ovarian Cancer
2. J5E-MC-JZXB Phase 3 · Eli Lilly and · Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neop
3. Mirvetuximab Soravtansine Phase 3 · AbbVie · Epithelial Ovarian Cancer
4. Mirvetuximab soravtansine plus Bevacizumab Phase 3 · AbbVie · Ovarian Cancer
5. IMGN853-0424 Phase 2 · AbbVie Deutschland GmbH · Recurrent Ovarian Cancer with High Folate Receptor-Alpha Exp
6. M25-709 Phase 2 · AbbVie Deutschland GmbH · Ovarian Cancer

1. mirvetuximab soravtansine-gynx Folate receptor alpha binding agent
2. mirvetuximab soravtansine Antineoplastic and immunomodulating agents (L01)

Frequently asked questions